AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 162 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,886 | -40.6% | 157 | -32.0% | 0.00% | -100.0% |
| Q2 2023 | $6,542 | +199.8% | 231 | +143.2% | 0.00% | – |
| Q1 2023 | $2,182 | -47.8% | 95 | -36.2% | 0.00% | -100.0% |
| Q4 2022 | $4,184 | +39.5% | 149 | +33.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | +50.0% | 112 | +51.4% | 0.00% | – |
| Q2 2022 | $2,000 | – | 74 | +572.7% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 11 | -88.5% | 0.00% | – |
| Q4 2021 | $3,000 | -50.0% | 96 | -28.9% | 0.00% | -100.0% |
| Q3 2021 | $6,000 | -14.3% | 135 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $7,000 | 0.0% | 135 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,000 | +16.7% | 135 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $6,000 | -14.3% | 135 | -27.8% | 0.00% | -50.0% |
| Q3 2020 | $7,000 | -30.0% | 187 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $10,000 | +100.0% | 187 | +38.5% | 0.00% | +50.0% |
| Q1 2020 | $5,000 | -16.7% | 135 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | – | 135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |